Shire To Launch Potential Dry Eye Blockbuster After FDA Backs Xiidra

Securing FDA approval for its novel dry eye treatment Xiidra (lifitegrast) gives Shire PLC a potential blockbuster and key future growth driver whose indication and label are more comprehensive than that of its closest approved rival.